{"id":"https://openalex.org/W1985487963","doi":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","title":"GPR40\u2010induced insulin secretion by the novel agonist TAK\u2010875: first clinical findings in patients with type 2 diabetes","display_name":"GPR40\u2010induced insulin secretion by the novel agonist TAK\u2010875: first clinical findings in patients with type 2 diabetes","publication_year":2011,"publication_date":"2011-11-03","ids":{"openalex":"https://openalex.org/W1985487963","doi":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","mag":"1985487963","pmid":"https://pubmed.ncbi.nlm.nih.gov/22051148"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01525.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"T. Araki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"T. Araki","raw_affiliation_strings":["Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan. takahiro.araki@tgrd.com","Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan. takahiro.araki@tgrd.com","institution_ids":["https://openalex.org/I44892455"]},{"raw_affiliation_string":"Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited Osaka, Japan","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010302035","display_name":"Masashi Hirayama","orcid":"https://orcid.org/0009-0008-6217-167X","observed_orcids":["https://orcid.org/0009-0008-6217-167X"]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"M. Hirayama","raw_affiliation_strings":["Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090544866","display_name":"Shinzo Hiroi","orcid":"https://orcid.org/0000-0002-0015-4793","observed_orcids":["https://orcid.org/0000-0002-0015-4793"]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"S. Hiroi","raw_affiliation_strings":["Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited, Osaka, Japan","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036190568","display_name":"Kohei Kaku","orcid":"https://orcid.org/0000-0003-1574-0565","observed_orcids":["https://orcid.org/0000-0003-1574-0565"]},"institutions":[{"id":"https://openalex.org/I189996419","display_name":"Kawasaki Medical School","ror":"https://ror.org/059z11218","country_code":"JP","type":"education","lineage":["https://openalex.org/I189996419"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"K. Kaku","raw_affiliation_strings":["Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan","institution_ids":["https://openalex.org/I189996419"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I44892455"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":8.2163,"has_fulltext":false,"cited_by_count":97,"citation_normalized_percentile":{"value":0.98163057,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"14","issue":"3","first_page":"271","last_page":"278"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gpr40","display_name":"GPR40","score":0.8339999914169312},{"id":"https://openalex.org/keywords/tak-875","display_name":"TAK-875","score":0.9470000267028809},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.7739999890327454},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.8320000171661377},{"id":"https://openalex.org/keywords/free-fatty-acids","display_name":"free fatty acids","score":0.9120000004768372},{"id":"https://openalex.org/keywords/g-protein-coupled-receptor-agonists","display_name":"G protein-coupled receptor agonists","score":0.8569999933242798},{"id":"https://openalex.org/keywords/oral-glucose-tolerance-test","display_name":"oral glucose tolerance test","score":0.8259999752044678},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8700000047683716},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.7839999794960022},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8700000047683716},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7319999933242798},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.5080000162124634},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.30399999022483826},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C32670627","wikidata":"https://www.wikidata.org/wiki/Q18026423","display_name":"Free fatty acid receptor 1","level":4,"score":0.8080710172653198},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7718679904937744},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7222477793693542},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6713245511054993},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6648041009902954},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6542262434959412},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6263630390167236},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6183891296386719},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5871492624282837},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5464791059494019},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.43156570196151733},{"id":"https://openalex.org/C2780833929","wikidata":"https://www.wikidata.org/wiki/Q1501412","display_name":"Glucose tolerance test","level":4,"score":0.4304697513580322},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3187482953071594},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.2522926330566406},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.10450819134712219},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000078790","descriptor_name":"Insulin Secretion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005951","descriptor_name":"Glucose Tolerance Test","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013450","descriptor_name":"Sulfones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01525.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01525.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:22051148","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22051148","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1499384204","https://openalex.org/W1525635171","https://openalex.org/W1971639453","https://openalex.org/W1995573327","https://openalex.org/W1999927420","https://openalex.org/W2018232315","https://openalex.org/W2019925176","https://openalex.org/W2020292843","https://openalex.org/W2027895941","https://openalex.org/W2040507092","https://openalex.org/W2048080194","https://openalex.org/W2054951377","https://openalex.org/W2077936393","https://openalex.org/W2094177994","https://openalex.org/W2098201060","https://openalex.org/W2102643074","https://openalex.org/W2113307670","https://openalex.org/W2128326754","https://openalex.org/W2138309074","https://openalex.org/W2139907919","https://openalex.org/W2140978079","https://openalex.org/W2147024197","https://openalex.org/W2150854800","https://openalex.org/W2159205789","https://openalex.org/W2163216300","https://openalex.org/W2165816400","https://openalex.org/W2172502596","https://openalex.org/W3035020636"],"related_works":["https://openalex.org/W2025703258","https://openalex.org/W2006474213","https://openalex.org/W7095953032","https://openalex.org/W2217706820","https://openalex.org/W7098103513","https://openalex.org/W2083245011","https://openalex.org/W4406057888","https://openalex.org/W2054951377","https://openalex.org/W2313705748","https://openalex.org/W2170455952"],"abstract_inverted_index":{"AIM:":[0],"Free":[1],"fatty":[2],"acids":[3],"act":[4],"as":[5,125],"signalling":[6],"molecules":[7],"for":[8,32,35,47,101,153],"modulating":[9],"insulin":[10,194],"secretion,":[11],"and":[12,18,87,92,95,145,159,166,177,203,234,272],"their":[13],"insulinotropic":[14,265],"effects":[15,115],"are":[16],"glucose-dependent":[17,264],"mediated":[19],"through":[20],"G":[21],"protein-coupled":[22],"receptor":[23],"40":[24],"(GPR40).":[25],"This":[26,72,186],"mechanism":[27],"is":[28],"a":[29,49,117,190,221],"potential":[30,266],"target":[31],"new":[33],"treatments":[34],"managing":[36],"diabetes.":[37],"In":[38],"this":[39],"study,":[40],"we":[41],"present":[42],"the":[43,85,250,263,268,273],"first":[44],"clinical":[45,275,281],"data":[46],"TAK-875,":[48,271],"novel":[50],"highly":[51],"selective,":[52],"orally":[53],"bioavailable":[54],"GPR40":[55,269],"agonist,":[56],"in":[57,116,133,193,215,224,253],"Japanese":[58],"patients":[59],"with":[60],"type":[61],"2":[62,102,106,167],"diabetes":[63],"insufficiently":[64],"controlled":[65],"by":[66,127,189,220],"diet":[67],"or":[68],"exercise":[69],"therapy.":[70],"METHODS:":[71],"was":[73,187,218],"an":[74],"exploratory":[75,258],"phase":[76],"II,":[77],"multicentre,":[78],"randomized,":[79],"double-blind,":[80],"parallel":[81],"group":[82],"study":[83],"comparing":[84],"efficacy":[86],"tolerability":[88],"of":[89,108,138,245,262,267],"TAK-875":[90,110,154,160],"100":[91,161],"400":[93,155],"mg,":[94],"placebo,":[96,164],"all":[97],"administered":[98],"once":[99],"daily":[100],"weeks.":[103],"RESULTS:":[104],"After":[105],"weeks":[107],"treatment,":[109],"produced":[111],"marked":[112],"glucose":[113,121,135,170,227],"lowering":[114],"75":[118],"g":[119],"oral":[120],"tolerance":[122],"test":[123],"(OGTT)":[124],"evidenced":[126],"mean":[128],"\u00b1":[129,140,147,172,179,198,205,229,236],"SE":[130],"intergroup":[131],"differences":[132],"plasma":[134,169,226,254],"AUC(0-3":[136,195],"h)":[137,196],"-12.98":[139],"1.48":[141],"(p":[142,150,174,182,200,207,231,239],"<":[143,151,175,183,201,208,232,240],"0.0001)":[144,176,233],"-8.12":[146],"1.49":[148],"mmol\u00b7h/l":[149],"0.0001),":[152,184,241],"mg":[156,162],"vs.":[157,163],"placebo":[158],"respectively,":[165],"h":[168],"[-4.95":[171],"0.71":[173,180],"-3.21":[178],"mmol/l":[181,238],"respectively].":[185,213,242],"accompanied":[188],"significant":[191,222,251],"increase":[192],"[34.68":[197],"12.16":[199],"0.01)":[202],"31.49":[204],"12.20":[206],"0":[209],"\u00b7":[210],"05)":[211],"\u00b5IU\u00b7h/ml,":[212],"Improvement":[214],"glycaemic":[216],"profile":[217],"mirrored":[219],"change":[223],"fasting":[225],"[-2.37":[228],"0\u00b727":[230],"-1.88":[235],"0.27":[237],"No":[243],"cases":[244],"hypoglycaemia":[246],"were":[247],"observed":[248],"despite":[249],"reduction":[252],"glucose.":[255],"CONCLUSIONS:":[256],"These":[257],"findings":[259],"provide":[260],"evidence":[261],"agonist":[270],"promising":[274],"changes":[276],"support":[277],"future":[278],"longer":[279],"term":[280],"investigation.":[282]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":20},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}